Pharmacological management of dermatomyositis.

about

Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

P2860

Q47593445-ABAF422C-826C-4D2A-BEA2-BBBD3C069879

P2860

Pharmacological management of dermatomyositis.

Item

http://www.wikidata.org/entity/Q39425296

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pharmacological management of dermatomyositis.

@en

Pharmacological management of dermatomyositis.

@nl

type

Item

label

Pharmacological management of dermatomyositis.

@en

Pharmacological management of dermatomyositis.

@nl

prefLabel

Pharmacological management of dermatomyositis.

@en

Pharmacological management of dermatomyositis.

@nl

P1476

Pharmacological management of dermatomyositis.

@en

P2093

Katalin Dankó

http://www.w3.org/2001/XMLSchema#string

Melinda Nagy-Vincze

http://www.w3.org/2001/XMLSchema#string

P2860

Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis

Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-

Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.

Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Polymyositis and dermatomyositis (first of two parts).

Tumor necrosis factor inhibitor-associated dermatomyositis

Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.

The management of dermatomyositis: current treatment options.

P304

1109-1118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2017.1353910

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zoltán Griger

P577

2017-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28691537

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis

Pharmacological management of dermatomyositis.

about

P2860

P2860

Pharmacological management of dermatomyositis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921